Cell cycle inhibition is one of the most successful targets to reduce proliferation and induce apoptosis in cancer cells. A number of potential molecular targets for novel anticancer drug discovery have been identified in cell cycle control mechanisms. Prominent among these are the regulatory proteins, cyclins and their effector counterparts the cyclin dependent kinases (CDKs). CDK inhibitors currently under investigation include flavopiridol, olomoucine, roscovitine, puvalanol B, the dihydroindolo, benzazepinone kenpaullone, indirubin-3-monoxime and novel diaminothiazoles.
In recent studies it has been shown that Cyclin Dependent Kinase 6 (CDK6) is one of the best targets to reduce the proliferation of cancers in particular cancers of childhood and early adolescence. Despite being an ideal target only one specific inhibitor is in clinical trials (PD0332991) and has shown inconsistent result with stabilisation of CDK6/Cyclin D complex. Based on this oncogene addiction paradigm, we want to test various small molecules (dibenzoyl-methane derivatives).
Grant Award – Studentship 2016-2017
Funding Award – £2000
Funding Awarded to – Dr Athar Aziz
Research Location – University of Salford
Lead Researcher – Dr Athar Aziz
0161 295 3864 